Back HIV/AIDS HIV/AIDS Topics HIV Prevention

Long-acting Injectable Cabotegravir Shows Promise as PrEP in Monkey Studies

A long-acting injected formulation of the HIV integrase inhibitor cabotegravir (GSK1265744) prevented infection of most macaque monkeys vaginally exposed to an HIV-like hybrid virus at drug concentrations achievable with monthly dosing, according to a pair of studies published in the January 14 issue of Science Translational Medicine.

alt

Read more:

HIV PrEP Forum Discusses Research, Personal Experiences, and Access

Nearly 100 people gathered on January 11 in San Francisco's Castro neighborhood to learn about the latest research on HIV pre-exposure prophylaxis -- better known as PrEP -- and how they can get help paying for it.

alt

Read more:

1. HIV PrEP: Rising Use, Promising New Truvada Data, More Future Options

PrEP, or pre-exposure prophylaxis to prevent HIV infection, was the major HIV topic in the mainstream media in 2014. 

alt

Read more:

Meta-Analysis Shows Injectable Hormonal Contraception Linked to HIV Infection Risk

Women who use the long-acting injectable contraceptive Depo-Provera had a modest but significant increase in the risk of contracting HIV infection, according to a meta-analysis of 12 studies published in the January 8Lancet Infectious Diseases. However, there was no increase in risk for women using birth control pills.

alt

Read more:

5. HIV Treatment as Prevention: No Infections in PARTNER Study

Pre-exposure prophylaxis (PrEP) for HIV negative people was the biggest topic in HIV prevention in 2014, but use of antiretroviral therapy by HIV positive people to prevent onward transmission of the virus -- dubbed treatment as prevention or TasP -- also received further support.

alt

Read more: